PortViewPortView
Paragon 28 logo

Paragon 28 (FNA) Stock Analysis

NYSEHealthcareMedical - Devices

$13.09+0.00%
1-year price historyRange $4.78 – $13.09
52-week range$13.09
$4.65$13.13

What Paragon 28 does

Paragon 28, Inc. is a medical device company specializing in the development, manufacturing, and global distribution of advanced surgical systems tailored for foot and ankle procedures. Its comprehensive product portfolio encompasses a wide array of solutions: Plating Systems: This includes the Gorilla plating series, offering specific solutions for Lisfranc injuries, Lapidus procedures, lateral column corrections, calcaneus slides, and naviculocuneiform (NC) fusions. Complementary products like Baby Gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates, as well as Silverback plating systems, are also available. Precision Guidance Technology: The company provides sophisticated guidance systems to enhance accuracy in various operations, such as fusion procedures for bunion deformities, first tarsometatarsal arthrodesis, metatarsal osteotomy for bunion correction, medial column beaming for Charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. Screw Systems: Paragon 28 offers robust screw systems, including the Monster, Mini Monster, and Joust beaming lines, which are critical for applications like bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, and fracture repair. Joint Replacement Solutions: Their offerings extend to total ankle replacement with the APEX 3D systems, alongside total talus spacers designed to replace the talus bone that links the leg and foot. Bunion/Hallux Valgus Correction Systems: Specifically for bunion management, the company provides nail systems such as the Phantom intramedullary nail systems, targeting severe hallux valgus cases. Orthobiologics: A substantial part of their product line comprises various orthobiologics, including bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix. They also feature PRESERVE bone graft systems for homologous applications. Ancillary Products: The company further supplies soft tissue fixation systems, titanium sprayed polyetheretherketone (PEEK) implants, nitinol staple systems, stabilization solutions, and specialized curved instruments. Paragon 28 distributes its products to hospitals and ambulatory surgery centers through an established network of both direct sales representatives and stocking distributors. Founded in 2010, the company maintains its corporate headquarters in Englewood, Colorado.

Key metrics

Market cap
$1.10B
P/E (TTM)
-19.83
EPS (TTM)
$-0.66
Beta
1.47
Dividend yield
0.00%
Revenue / share
$3.07
50-day avg
$13.03
200-day avg
$9.71
52-week high
$13.13
52-week low
$4.65
CEO
Albert DaCosta

ETFs linked to FNA

Broad-market and Healthcare sector ETFs an investor holding Paragon 28 is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how FNA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze FNA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Paragon 28?
Paragon 28 trades under the ticker FNA on NYSE.
Which exchange is FNA listed on?
FNA is listed on NYSE.
What sector does Paragon 28 operate in?
Paragon 28 is classified in the Healthcare sector (Medical - Devices industry).
How can PortView help analyze FNA in a portfolio?
PortView shows FNA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.